AI Analysis
AI-generated analysis. Always verify with the original filing.
Innate Pharma S.A. filed its 2025 Universal Registration Document with the AMF and Form 20-F annual report with the SEC on April 1, 2026, both accessible on company and regulatory websites.
Key Takeaways
1Filed 2025 Universal Registration Document (Document d’enregistrement universel) with AMF on April 1, 2026.
2Filed 2025 Form 20-F annual report for year ended December 31, 2025 with SEC on April 1, 2026.
3Universal Registration Document incorporates annual financial report, management report, corporate governance report, and Statutory Auditors report.
4Documents available for download on Innate Pharma’s website and AMF/SEC websites.
5Innate Pharma develops immunotherapies including IPH4502, lacutamab, and monalizumab in collaboration with AstraZeneca.